Affiliation:
1. Office of Clinical Pharmacology, Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring MD USA
2. Office of Pharmaceutical Quality, Office of Biotechnology Products, Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring MD USA
Abstract
AbstractPediatric obesity is a global public health concern. Obesity‐related physiological changes may affect the pharmacokinetics of drugs and lead to therapeutic failure or toxicities. An earlier review of pediatric drug development programs from 2007 to 2016 found that, of 89 programs listing obesity‐related terms, only 4 (4%) products described pharmacokinetic changes associated with obesity. This review examined obesity considerations for 185 drug products for which pediatric drug development programs were submitted to the US Food and Drug Administration (FDA) between 2016 and 2021. The FDA‐authored review documents and drug product labeling were queried for obesity‐related terms and the review found 97/185 (52%) drug products had obesity‐related terms in these sources. Of the 97 drug products, 55/97 (57%) had obesity‐related terms in the FDA‐authored reviews only, 13/97 (13%) had obesity‐related terms in the drug product labeling only, and 29/97 (30%) had obesity‐related terms in both FDA‐authored reviews and drug product labeling. Most of the obesity‐related information in the drug product labeling originated from data collected from adults. Only 13/185 (7%) drug product labeling contained obesity‐related terms in reference to drug pharmacokinetics. Specific dosage recommendations for the use of the drug products in pediatric patients who are obese remain lacking. The dearth of available information to guide drug dosages in the obese pediatric population suggests that further research, innovative approaches, and evidence‐based guidelines are needed to inform the optimal therapeutic use of drugs in this population.
Subject
Pharmacology (medical),Pharmacology
Reference28 articles.
1. Centers for Disease Control and Prevention.Defining childhood weight status: BMI for children and teens. Accessed February 27 2023.https://www.cdc.gov/obesity/basics/childhood‐defining.html
2. Centers for Disease Control and Prevention.Defining adult overweight & obesity. Accessed May 8 2023.https://www.cdc.gov/obesity/basics/adult‐defining.html?CDC_AA_refVal
3. Health Effects of Overweight and Obesity in 195 Countries over 25 Years
4. National health and nutrition examination survey 2017–march 2020 prepandemic data files—Development of files and prevalence estimates for selected health outcomes;Stierman BA;Natl Health Stat Rep,2021
5. Pediatric Obesity: Influence on Drug Dosing and Therapeutics